VANNUCCHI, ALESSANDRO MARIA

VANNUCCHI, ALESSANDRO MARIA  

Medicina Sperimentale e Clinica  

Mostra records
Risultati 1 - 20 di 604 (tempo di esecuzione: 0.021 secondi).
Titolo Data di pubblicazione Autore(i) File
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events 2022 Gangat, Naseema; Szuber, Natasha; Jadoon, Yamna; Farrukh, Faiqa; Begna, Kebede; Elliott, Michelle A; Wolanskyj-Spinner, Alexandra P; Hanson, Curtis A; Pardanani, Animesh D; De Stefano, Valerio; Barbui, Tiziano; Vannucchi, Alessandro Maria; Tefferi, Ayalew
[Essential thrombocythemia: conventional therapy] 1991 A. Grossi; A. M. Vannucchi; G. Longo; D. Rafanelli; P. Rossi Ferrini
[GM-CSF: its clinical administration; the treatment of aplasia] 1989 P. Rossi Ferrini; A. Grossi; V. Santini; A. M. Vannucchi
A blood drop through the pore: nanopore sequencing in hematology 2021 Bartalucci N.; Romagnoli S.; Vannucchi A.M.
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 2020 Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M.
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 2018 Loscocco, Giuseppe G; Piccini, Matteo; Vergoni, Federica; Vannucchi, Alessandro M; Bosi, Alberto
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 2017 Passamonti, F.; Giorgino, T.; Mora, B.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J. J.; Cervantes, F.; Devos, T.; Palandri, F.; De Stefano, V.; Ruggeri, M.; Silver, R. T.; Benevolo, G.; Albano, F.; Caramazza, D.; Merli, M.; Pietra, D.; Casalone, R.; Rotunno, G.; Barbui, T.; Cazzola, M.; Vannucchi, A. M.
A common megakaryocytic and erythrocytic precursor in murine erythroleukemia (Friend) cells? 1994 A. VANNUCCHI; PAOLETTI F.; GROSSI A.
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 2016 Calura, E; Pizzini, S; Bisognin, A; Coppe, A; Sales, G; Gaffo, E; Fanelli, T; Mannarelli, C; Zini, R; Norfo, R; Pennucci, V; Manfredini, R; Romualdi, C; Guglielmelli, P; Vannucchi, A M; Bortoluzzi, S
A dot assay for the erythropoietin receptor using human recombinant 125I-erythropoietin. 1989 A. M. Vannucchi; A. Grossi; D. Rafanelli; L. Vannucchi; P. R. Ferrini
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 2010 Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A.
A life-threatening ruxolitinib discontinuation syndrome 2017 Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 2014 F. Lussana;A. Carobbio;M. L. Randi;C. Elena;E. Rumi;G. Finazzi;I. Bertozzi;L. Pieri;M. Ruggeri;F. Palandri;N. Polverelli;E. Elli;A. Tieghi;A. Iurlo;M. Ruella;M. Cazzola;A. Rambaldi;A. M. Vannucchi;T. Barbui
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 2020 Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Chiara Cavalloni, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Maria Chiara Finazzi, Juergen Thiele, Alessandro M. Vannucchi, Ayalew Tefferi,Tiziano Barbui
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 2009 Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis 2005 VANNUCCHI AM.; BIANCHI L.; F. PAOLETTI; PANCRAZZI A.; TORRE E.; NISHIKAWA M.; ZINGARIELLO M.; DI BALDASSARRE A.; RANA RA.; LORENZINI R.; ALFANI E.; MIGLIACCIO G.; MIGLIACCIO AR.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 2014 Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis 2022 Harrison, Claire; Heidel, Florian H; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Hayat, Amjad; Passamonti, Francesco; Conneally, Eibhlin; Kindler, Thomas; Martino, Bruno; Lipka, Daniel B; Stefanelli, Tommaso; Roussou, Pantelia; Germano, Davide; Ewan, Jacqueline; Ribrag, Vincent
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. 2013 Finazzi G;Vannucchi AM;Martinelli V;Ruggeri M;Nobile F;Specchia G;Pogliani EM;Olimpieri OM;Fioritoni G;Musolino C;Cilloni D;Sivera P;Barosi G;Finazzi MC;Di Tollo S;Demuth T;Barbui T;Rambaldi A
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. 2010 Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T.